Portal de Periódicos da CAPES

Race, Ancestry, and Risk: Targeting Prevention to Address Heart Failure Disparities

2021; Lippincott Williams & Wilkins; Volume: 15; Issue: 1 Linguagem: Inglês

10.1161/circheartfailure.121.008741

1941-3297

Quentin R. Youmans, Donald M. Lloyd‐Jones, Sadiya S. Khan,

Cardiovascular Issues in Pregnancy

HomeCirculation: Heart FailureVol. 15, No. 1Race, Ancestry, and Risk: Targeting Prevention to Address Heart Failure Disparities Free AccessArticle CommentaryPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessArticle CommentaryPDF/EPUBRace, Ancestry, and Risk: Targeting Prevention to Address Heart Failure Disparities Quentin R. Youmans, MD, MSc, Donald M. Lloyd-Jones, MD, ScM and Sadiya S. Khan, MD, MSc Quentin R. YoumansQuentin R. Youmans https://orcid.org/0000-0001-5818-8091 Division of Cardiology, Department of Medicine (Q.R.Y., S.S.K.), Northwestern University Feinberg School of Medicine, Chicago, IL. , Donald M. Lloyd-JonesDonald M. Lloyd-Jones https://orcid.org/0000-0003-0847-6110 Department of Preventive Medicine (D.M.L.-J., S.S.K.), Northwestern University Feinberg School of Medicine, Chicago, IL. and Sadiya S. KhanSadiya S. Khan Correspondence to: Sadiya S. Khan, MD, MSc, Northwestern University, Feinberg School of Medicine, 680 N Lakeshore Dr, Ste 1400, Chicago, IL 60611. Email E-mail Address: [email protected] https://orcid.org/0000-0003-0643-1859 Division of Cardiology, Department of Medicine (Q.R.Y., S.S.K.), Northwestern University Feinberg School of Medicine, Chicago, IL. Department of Preventive Medicine (D.M.L.-J., S.S.K.), Northwestern University Feinberg School of Medicine, Chicago, IL. Originally published22 Dec 2021https://doi.org/10.1161/CIRCHEARTFAILURE.121.008741Circulation: Heart Failure. 2022;15:e008741Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: December 22, 2021: Ahead of Print Race-based disparities in heart failure (HF) are greater than disparities in all other cardiovascular disease subtypes in the United States. There is an estimated 20-fold higher incidence rate of and a 3-fold higher mortality rate due to HF in young Black adults compared with young White adults.1 Addressing racial disparities in HF should begin before the manifestations of overt disease and requires multi-level interventions, including the need to address contributions of structural racism. Comprehensive risk assessment may enhance our ability to intensify prevention efforts in those at greatest risk for HF. Importantly, this must start with the acknowledgement that race is a social construct and not a biological one.2 With that foundational understanding, this perspective discusses the value of multivariate risk prediction, contextualizing social factors that reclassify risk, and integrating and expanding knowledge on genetic variants for HF in diverse populations to develop a comprehensive approach towards equitable prevention of HF.Traditional Risk FactorsThe foundation of our preventive efforts must begin with addressing traditional HF risk factors. Black Americans have among the highest rates of hypertension in the world.3 Once diagnosed, Black patients have lower prevalence of control. The reasons for the higher rates of suboptimal control are complex and interrelated and due primarily to social, environmental, and behavioral factors.4 Equitably targeting intensive blood pressure (BP) lowering in those at high HF risk will be imperative to reduce disparities in HF. Risk equations that have been validated in diverse cohorts, such as the Pooled Cohort Equation to Prevent Heart Failure, may help identify individuals at high risk of HF.5 These risk equations include race-specific coefficients for variables such as age, sex, cholesterol levels, BP, diabetes status, and smoking status. Because race is a social construct, it was not used as a covariate and should not be treated as causative. These race-specific models were derived based on self-reported race, but future models that remove race and focus on other variables reflecting social determinants of health (eg, insurance status, educational attainment, or zip code) are needed. Root causes of health disparities in HF risk factors are due to disproportionate exposure to adversity (including overt racism) and other barriers to care. These are socially mediated burdens and not due to race as a monolithic risk factor. Through greater understanding of these factors can optimal and personalized preventive interventions be taken to mitigate HF disparities.Integrating Social DeterminantsWhile risk of HF is largely related to modifiable risk factors, this risk is potentiated by the confluence of adverse social factors experienced by minoritized individuals (eg, social determinants of health). In the United States, anti-Black racism shapes these forces such that Black Americans, structurally, have a higher burden of detrimental social determinants.6 A variety of social determinants of health (eg, low educational attainment, low annual household income, zip code poverty, poor public health infrastructure, and lack of health insurance) have been associated with incident HF.7 These must be addressed to adequately address HF risk. Based on literature demonstrating associations between self-reported experiences of unfair treatment and hypertension, it reasonable to infer that racism and bias may impact HF risk. These data portray the multifactorial nature of HF risk and highlight that structures, not biological differences, are the primary drivers of risk.8Ancestry and GeneticsIt is well-established that both environmental and genetic risk factors contribute to risk of HF.9 Heritability estimates for HF range from 26% to 34%, and there are an increasing number of genetic variants identified to be associated with HF. The advent and rapid development of sophisticated large-scale genetic sequencing has fueled important discoveries in HF biology, but this work has been conducted in populations predominantly of European ancestry. This is challenging as lack of diversity in available genetic data hampers understanding of genetic drivers of risk. For example, a common variant in transthyretin, V122I affects ≈4% of individuals of African ancestry.10 This variant is associated with more than a 2-fold higher risk of HF, but a novel therapy that targets the transthyretin protein is available. Hence, there is a pressing need to expand the size and number of studies involving those of African ancestry to identify genetic risk factors for HF that may be unique to this ancestral group.However, it is important not to conflate ancestry and race; the former specifically relates to genetic population structures that are correlated with biogeographic origins, and the latter is a social construct used to categorize individuals within a population. Race is, therefore, imbued with other sociocultural and political factors, biases, and racism. Investigators who study genetic associations in diverse populations must be cognizant of how their findings are presented and interpreted. They should be cautious to ensure that their findings are not used erroneously and maliciously to support supremacist agendas, as has happened in the past.Charting the Path ForwardHow should these data inform research and clinical practice (Figure)? First, we must be relentless in our mission to dismantle the ubiquitous systems of racism. Second, we must redouble our efforts to enhance risk communication and focus on improving implementation of evidence-based strategies for our Black patients at greatest risk of HF. We can also engender trust by further diversifying our physician and nonphysician workforce (eg, clinical pharmacists, advanced practice practitioners). More effective workforce utilization could include transitioning care from the clinic or hospital setting into the home (eg, home BP monitoring).11 We should, moreover, expand our definition of the classic health care team to include community health workers. Together, we should prioritize meeting patients where they are and providing comprehensive risk factor modification that incorporates social determinants of health.12 Once risk is relayed, we should consider disruptive approaches to mitigate these disparities in risk. Approaches to consider include embedding interventions in community settings like the barbershop,13 employing different delivery strategies such as fixed-dose combination drug therapies,14 and altering policies to support healthier dietary patterns like Dietary Approaches to Stop Hypertension and plant-based diets. In addition, policies to increase health care access and affordability are needed.Download figureDownload PowerPointFigure. Recommendations for addressing race and risk in heart failure. Summarized in the figure are key recommendations, considerations for potential policy recommendations, and potential clinician-level impact.ConclusionsAs comprehensive risk-based strategies increasingly incorporate multi-dimensional risk associated with race in the United States, we may be able to mitigate disparities in HF that exist by earlier identification and intervention. Quantification of HF risk should account for adverse social factors that enhance risk and highlight the unique risk borne by Black adults due to structural racism. Strategies to target risk will need to include community-engaged approaches and advocacy for policy changes to equitably promote cardiovascular health. While we are dismantling the systems that perpetuate racial disparities, we must acknowledge their existence and integrate this into our actions for equitable prevention of HF.Article InformationSources of FundingSupported by grants from the National Institutes of Health/National Heart, Lung, and Blood Institute (KL2TR001424) and the American Heart Association (19TPA34890060) to Dr Khan and Sarnoff Cardiovascular Research Foundation Fellowship to Jacob Pierce. Research reported in this publication was supported, in part, by the National Institutes of Health's National Center for Advancing Translational Sciences, grant KL2TR001424 (Dr Khan). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.AcknowledgmentsThe funding sponsor did not contribute to design and conduct of the study, collection, management, analysis, or interpretation of the data or preparation, review, or approval of the article. The authors take responsibility for decision to submit the article for publication.DisclosuresNone.FootnotesFor Sources of Funding and Disclosures, see page 109.The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.Correspondence to: Sadiya S. Khan, MD, MSc, Northwestern University, Feinberg School of Medicine, 680 N Lakeshore Dr, Ste 1400, Chicago, IL 60611. Email [email protected]eduReferences1. Bibbins-Domingo K, Pletcher MJ, Lin F, Vittinghoff E, Gardin JM, Arynchyn A, Lewis CE, Williams OD, Hulley SB. Racial differences in incident heart failure among young adults.N Engl J Med. 2009; 360:1179–1190. doi: 10.1056/NEJMoa0807265CrossrefMedlineGoogle Scholar2. Collins FS. What we do and don't know about 'race', 'ethnicity', genetics and health at the dawn of the genome era.Nat Genet. 2004; 36(Suppl 11):S13–S15. doi: 10.1038/ng1436CrossrefMedlineGoogle Scholar3. Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Cheng S, Delling FN, et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2021 update: a report from the American Heart Association.Circulation. 2021; 143:e254–e743. doi: 10.1161/CIR.0000000000000950LinkGoogle Scholar4. Rao S, Segar MW, Bress AP, Arora P, Vongpatanasin W, Agusala V, Essien UR, Correa A, Morris AA, de Lemos JA, Pandey A, et al. Association of genetic West African ancestry, blood pressure response to therapy, and cardiovascular risk among self-reported black individuals in the Systolic Blood Pressure Reduction Intervention Trial (SPRINT).JAMA Cardiol. 2020; 6:388–398. doi: 10.1001/jamacardio.2020.6566CrossrefGoogle Scholar5. Khan SS, Ning H, Shah SJ, Yancy CW, Carnethon M, Berry JD, Mentz RJ, O'Brien E, Correa A, Suthahar N, et al. 10-Year risk equations for incident heart failure in the general population.J Am Coll Cardiol. 2019; 73:2388–2397. doi: 10.1016/j.jacc.2019.02.057CrossrefMedlineGoogle Scholar6. Borrell LN, Elhawary JR, Fuentes-Afflick E, Witonsky J, Bhakta N, Wu AHB, Bibbins-Domingo K, Rodríguez-Santana JR, Lenoir MA, Gavin JRet al. Race and genetic ancestry in medicine - a time for reckoning with racism.N Engl J Med. 2021; 384:474–480. doi: 10.1056/NEJMms2029562CrossrefMedlineGoogle Scholar7. Pinheiro LC, Reshetnyak E, Sterling MR, Levitan EB, Safford MM, Goyal P. Multiple vulnerabilities to health disparities and incident heart failure hospitalization in the REGARDS study.Circ Cardiovasc Qual Outcomes. 2020; 13:e006438. doi: 10.1161/CIRCOUTCOMES.119.006438LinkGoogle Scholar8. Luzum JA, Peterson E, Li J, She R, Gui H, Liu B, Spertus JA, Pinto YM, Williams LK, Sabbah HN, et al. Race and beta-blocker survival benefit in patients with heart failure: an investigation of self-reported race and proportion of African genetic ancestry.J Am Heart Assoc. 2018; 7:e007956. doi: 10.1161/JAHA.117.007956LinkGoogle Scholar9. Cresci S, Pereira NL, Ahmad F, Byku M, de Las Fuentes L, Lanfear DE, Reilly CM, Owens AT, Wolf MJ. Heart failure in the era of precision medicine: a scientific statement from the American Heart Association.Circ Genom Precis Med. 2019; 12:458–485. doi: 10.1161/HCG.0000000000000058LinkGoogle Scholar10. Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, Buxbaum JN. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans.N Engl J Med. 1997; 336:466–473. doi: 10.1056/NEJM199702133360703CrossrefMedlineGoogle Scholar11. Pezzin LE, Feldman PH, Mongoven JM, McDonald MV, Gerber LM, Peng TR. Improving blood pressure control: results of home-based post-acute care interventions.J Gen Intern Med. 2011; 26:280–286. doi: 10.1007/s11606-010-1525-4CrossrefMedlineGoogle Scholar12. Ibe CA, Alvarez C, Carson KA, Marsteller JA, Crews DC, Dietz KB, Greer RC, Bone L, Cooper LA; RICH LIFE Study Investigators. Social determinants of health as potential influencers of a collaborative care intervention for patients with hypertension.Ethn Dis. 2021; 31:47–56. doi: 10.18865/ed.31.1.47CrossrefMedlineGoogle Scholar13. Victor RG, Lynch K, Li N, Blyler C, Muhammad E, Handler J, Brettler J, Rashid M, Hsu B, Foxx-Drew Det al. A cluster-randomized trial of blood-pressure reduction in black barbershops.N Engl J Med. 2018; 378:1291–1301. doi: 10.1056/NEJMoa1717250CrossrefMedlineGoogle Scholar14. Muñoz D, Uzoije P, Reynolds C, Miller R, Walkley D, Pappalardo S, Tousey P, Munro H, Gonzales H, Song W, et al. Polypill for cardiovascular disease prevention in an underserved population.N Engl J Med. 2019; 381:1114–1123. doi: 10.1056/NEJMoa1815359CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited BySegar M, Keshvani N, Rao S, Fonarow G, Das S and Pandey A (2022) Race, Social Determinants of Health, and Length of Stay Among Hospitalized Patients With Heart Failure: An Analysis From the Get With The Guidelines-Heart Failure Registry, Circulation: Heart Failure, 15:11, (e009401), Online publication date: 1-Nov-2022. Biondi-Zoccai G, Peruzzi M and Frati G (2022) Is Smoking Cessation the Best Intervention Ever to Prevent Heart Failure?, Journal of the American College of Cardiology, 10.1016/j.jacc.2022.04.006, 79:23, (2306-2309), Online publication date: 1-Jun-2022. January 2022Vol 15, Issue 1 Advertisement Article InformationMetrics © 2021 American Heart Association, Inc.https://doi.org/10.1161/CIRCHEARTFAILURE.121.008741PMID: 34933571 Originally publishedDecember 22, 2021 Keywordsblood pressureprevalencecholesterolsmokingheart failurePDF download Advertisement SubjectsDisparitiesHealth EquityHeart FailureSocial Determinants of Health